© Copyright 2016 The KINDReD ASSOCIATION. All rights reserved.
HOME MEMBERS NEGLECTED PARASITIC DISEASES DRUG DEVELOPMENT PIPELINE NEWS & PUBLICATIONS JOIN US CONTACT
Made in France

DRUG DEVELOPMENT

Most of the affected populations have very limited purchasing power

(some living with approximatly €1 per day), and thus attract little

interest from the major pharmaceutical companies.

The drugs currently used for the treatment of these diseases were developed decades ago and have serious limitations due to toxicity or lack of efficacy.

Currently, multiple treatments exist for these diseases, but none

reach all the requirements of these diverse pathologies.

There is clearly an urgent need to develop safer and more effective chemotherapies to reduce the burden caused by neglected infectious diseases. Given the challenges and low success rate in moving drug discovery programs to the patients, it is critical to have a broader portfolio of potential therapeutics moving forward in the pipeline, especially in the field of neglected diseases. The KINDReD Consortium via The KINDReD Association aims to fill this gap, combining academic excellence from topnotch research organisations and biotech expertise, to form an association of public- private partnerships aimed at delivering clinical candidates for these diseases.
Together, we will win against  neglected infectious diseases.
DRUG DEVELOPMENT
© Copyright 2016 The KINDReD ASSOCIATION. All rights reserved.
NAVIGATION MENU
Made in France

DRUG

DEVELOPMENT

Most of the affected

populations have very limited

purchasing power (some living

with approximatly €1 per day),

and thus attract little interest

from the major pharmaceutical

companies.

The drugs currently used for the treatment of these diseases were developed decades ago and have serious limitations due to toxicity or lack of efficacy.

Currently, multiple

treatments exist for

these diseases, but

none reach all the

requirements of these

diverse pathologies.

There is clearly an urgent need to develop safer and more effective chemotherapies to reduce the burden caused by neglected infectious diseases. Given the challenges and low success rate in moving drug discovery programs to the patients, it is critical to have a broader portfolio of potential therapeutics moving forward in the pipeline, especially in the field of neglected diseases. The KINDReD Consortium via The KINDReD Association aims to fill this gap, combining academic excellence from topnotch research organisations and biotech expertise, to form an association of public-private partnerships aimed at delivering clinical candidates for these diseases.
Together, we will win against  neglected infectious diseases.